Schroder Investment Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Schroder Investment Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-277,515	Closed	-$4.6M	–	1239
2023 Q1	$4.6M	Buy	+277,515	New	+$4.58M	0.01%	800
2021 Q2	–	Sell	-767,041	Closed	-$3.54M	–	1532
2021 Q1	$3.54M	Sell	767,041 -145,486	-16%	-$578K	﹤0.01%	898
2020 Q4	$3.05M	Sell	912,527 -114,860	-11%	-$386K	﹤0.01%	915
2020 Q3	$3.13M	Sell	1,027,387 -624,824	-38%	-$2.44M	0.01%	816
2020 Q2	$7.63M	Buy	1,652,211 +323,645	+24%	+$1.45M	0.01%	612
2020 Q1	$5.21M	Buy	1,328,566 +974,809	+276%	+$4M	0.01%	660
2019 Q4	$1.33M	Buy	+353,757	New	+$1.65M	﹤0.01%	934

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group's CPRX Position: Q2 2023 in Review

Schroder Investment Management Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 277,515 shares — an estimated $4.6M sold.

Schroder Investment Management Group first reported a position in CPRX in Q4 2019 and held it in 7 quarters. The position peaked at $7.63M in Q2 2020. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

Schroder Investment Management Group reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Schroder Investment Management Group sold 277,515 Catalyst Pharmaceutical shares in Q2 2023, an estimated $4.6M.
Schroder Investment Management Group first reported a position in Catalyst Pharmaceutical in Q4 2019 and held it in 7 quarters.
Schroder Investment Management Group's Catalyst Pharmaceutical position peaked at $7.63M in Q2 2020.
248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on Schroder Investment Management Group's 13F filing for Q2 2023, filed 11 Aug 2023.